scholarly journals Bilateral thyroid adenomas in an alpaca

2021 ◽  
Author(s):  
Kate Burbery ◽  
Olivier Simon ◽  
Lucy Woolford ◽  
Gustavo Ferlini Agne
Keyword(s):  
Thyroid Adenomas

Truncations of the THADA gene are involved in the development of thyroid adenomas with 2p21 aberrations

2004 ◽  
Vol 112 (S 1) ◽  
Author(s):  
G Belge ◽  
N Driescner ◽  
M Meiboom ◽  
HM Escobar ◽  
U Bonk ◽  
...  
Keyword(s):  
Thyroid Adenomas

scholarly journals Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas

Diagnostics ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 43
Author(s):  
Armida Sodo ◽  
Martina Verri ◽  
Andrea Palermo ◽  
Anda Mihaela Naciu ◽  
Marialuisa Sponziello ◽  
...  
Keyword(s):  
Raman Spectroscopy ◽  
Thyroid Nodules ◽  
Thyroid Neoplasms ◽  
Molecular Profile ◽  
Molecular Fingerprint ◽  
Extensive Evaluation ◽  
Associated Proteins ◽  
Thyroid Adenomas ◽  
Malignant Lesions ◽  
Nuclear Features

Follicular patterned nodules are sometimes complex to be classified due to ambiguous nuclear features and/or questionable capsular or vascular invasion. In this setting, there is a poor inter-observer concordance even among expert pathologists. Raman spectroscopy was recently used to separate benign and malignant thyroid nodules based on their molecular fingerprint; anyway, some histologically proved follicular adenomas were clustered as having a characteristic profile of malignant lesions. In this study, we analyzed five follicular thyroid adenomas with a malignant spectroscopic profile compared to five follicular adenomas with a benign Raman spectrum in order to assess possible molecular differences between the two groups. Morphological, immunohistochemical, and molecular analyses evidenced expression of malignancy-associated proteins in four out of five malignant clustered adenomas. The remaining malignant clustered adenoma showed a TSHR mutation previously associated with autonomously functioning follicular carcinomas. In conclusion, thyroid follicular adenomas are a group of morphologically benign neoplasms that may have altered the mutational or expression profile; cases of adenomas with altered immunophenotype are recognized as showing a profile associated with malignancy by Raman spectroscopy. This correlation warrants a more extensive evaluation and suggests a potential predictive value of spectroscopic assessment in recognizing characteristics associated with tumor progression in follicular thyroid neoplasms.

scholarly journals TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population

2015 ◽  
Vol 22 (6) ◽  
pp. 901-908 ◽  
Author(s):  
Ebtesam Qasem ◽  
Avaniyapuram Kannan Murugan ◽  
Hindi Al-Hindi ◽  
Mingzhao Xing ◽  
Mai Almohanna ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Middle East ◽  
Direct Sequencing ◽  
Tumour Size ◽  
Middle Eastern ◽  
Middle Eastern Population ◽  
Thyroid Adenomas ◽  
Cell Variant ◽  
Hürthle Cell Thyroid Cancer ◽  
Promoter Mutations

Telomerase reverse transcriptase (TERT) promoter mutations C228T and C250T have recently been described in follicular cell-derived thyroid cancer (TC) in patients from North America and Europe. In this study, we explored whether these findings could be replicated in patients from a different ethnic group. We screened 17 benign thyroid adenomas and 265 TC samples from patients in the Middle East for these mutations by PCR and direct sequencing using DNA isolated from paraffin-embedded tumor tissues. None of the 17 benign adenomas harbored TERT promoter mutations. Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC. C250T mutation was present in only 6/265 (2.3%) cases, while C228T mutation was present in a total of 28/265 (10.6%) cases. These two mutations were mutually exclusive. TERT promoter mutations were significantly more common in older (≥45 years) than younger patients and were associated with larger tumour size, vascular invasion, higher TNM stage (stage III and IV), BRAFV600E mutation and persistent/recurrent disease at 6–12 months after initial treatment and at the last follow up. These associations were stronger in non-CPTC. Thus, this study on a large cohort of TC patients from Middle East demonstrates that TERT promoter mutations are relatively common, especially in the non-CPTC, and are associated with more aggressive histopathological features, BRAFV600E mutation, and disease persistence/recurrence than the WT TERT.

BRONCHIAL CARCINOID ACCOMPANIED BY THYROID ADENOMAS AND ADRENAL ADENOMAS

1977 ◽  
Vol 27 (3) ◽  
pp. 375-385
Author(s):  
Hiroshi Kaneko ◽  
Haruto Hōjō ◽  
Shinobu Ishikawa ◽  
Michio Kikuchi
Keyword(s):  
Bronchial Carcinoid ◽  
Thyroid Adenomas

Feline Thyroid Adenomas are in Part Associated with Mutations in the Gsα Gene and not with Polymorphisms Found in the Thyrotropin Receptor

Thyroid ◽  
2002 ◽  
Vol 12 (7) ◽  
pp. 571-575 ◽  
Author(s):  
Marijke E. Peeters ◽  
Elpetra P.M. Timmermans-Sprang ◽  
Jan A. Mol
Keyword(s):  
Thyrotropin Receptor ◽  
Gsα Gene ◽  
Thyroid Adenomas

scholarly journals Ultrasound - first imaging modality in the detection of parathyroid adenomas

2008 ◽  
Vol 12 (3) ◽  
pp. 64 ◽  
Author(s):  
R Ahmed ◽  
N Khan ◽  
S Ellemdin ◽  
K Gayaparsad
Keyword(s):  
Nuclear Medicine ◽  
High Resolution ◽  
Gold Standard ◽  
Imaging Modality ◽  
Non Invasive ◽  
Highly Sensitive ◽  
Parathyroid Adenomas ◽  
Thyroid Adenomas ◽  
Invasive Method ◽  
Ultrasound Features

Abstract We present a series of 12 patients in whom the typical ultrasound features of parathyroid adenomas were accurately demonstrated. High resolution ultrasound [in experienced hands] is a highly sensitive accurate, safe and non invasive method of localizing parathyroid adenomas especially in patients with typically located glands and an absence of thyroid pathology. Our aim was to compare ultrasound with nuclear medicine as an imaging gold standard in patients with thyroid adenomas.

scholarly journals A Rare Case of Heterozygous Gain of Function Thyrotropin Receptor Mutation Associated with Development of Thyroid Follicular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
James Blackburn ◽  
Dinesh Giri ◽  
Barbara Ciolka ◽  
Nicole Gossan ◽  
Mohammad Didi ◽  
...  
Keyword(s):  
Thyroid Nodule ◽  
Clinical Presentation ◽  
Follicular Carcinoma ◽  
Thyroid Function Tests ◽  
Thyrotropin Receptor ◽  
Nuclear Pleomorphism ◽  
Activating Mutations ◽  
Thyroid Adenomas ◽  
Thyroid Follicular Carcinoma ◽  
First Time

Activating mutations in thyrotropin receptor (TSHR) have been previously described in the context of nonautoimmune hyperthyroidism and thyroid adenomas. We describe, for the first time, a mutation inTSHRcontributing to follicular thyroid carcinoma (FTC) in an adolescent. A 12-year-old girl presented with a right-sided neck swelling, increasing in size over the previous four weeks. Clinical examination revealed a firm, nontender thyroid nodule. Ultrasound scan of the thyroid showed a heterogeneous highly vascular mass. Thyroid function tests showed suppressed TSH [<0.03mU/L], normal FT4 [10.1pmol/L, 9-19], and raised FT3 [9.1pmol/L, 3.6-6.4]. Thyroid [TPO and TRAB] antibodies were negative. A right hemithyroidectomy was performed and the histology of the sample revealed follicular carcinoma with mild to moderate nuclear pleomorphism and evidence of capsular and vascular invasion (pT1b). Sanger sequencing of DNA extracted from the tumour tissue revealed a missense somatic mutation (c.1703T>C, p.Ile568Thr) inTSHR. Papillary thyroid carcinomas constitute the most common thyroid malignancy in childhood, while FTC is rare. FTC due toTSHRmutation suggests an underlying, yet to be explored, molecular pathway leading to the development of malignancy. The case is also unique in that the clinical presentation of FTC as a toxic thyroid nodule has not been previously reported in children.

Sign in / Sign up

Export Citation Format

Share Document